Invitae

What Invitae does

Invitae is a medical genetics company that delivered comprehensive genetic testing services across oncology, women's health, cardiology, neurology, pediatrics, rare diseases, and proactive genetic risk screening. Its core technology stack combined next-generation sequencing (NGS) laboratories certified under CLIA and CAP standards with two proprietary technology layers: the Invitae Generation variant classification platform (a machine-learning-augmented system achieving 99%+ stability in definitive classifications and a 40% reduction in variants of uncertain significance since 2020, trained on a database of 2 million+ classified unique variants and 1.7 million ClinVar submissions) and the Gia chatbot (a HIPAA-compliant NLP-driven virtual assistant for patient intake, education, and results delivery, used by 100,000+ patients). Products spanned condition-specific multi-gene panels (e.g., 71-gene Multi-Cancer Panel, 9-gene Hereditary Breast Cancer STAT Panel, 320-gene Epilepsy Panel, 230-gene Comprehensive Neuromuscular Disorders Panel), whole exome sequencing, and post-acquisition liquid biopsy (Plasma Detect ID MRD).

The business model was a B2B healthcare provider channel: clinicians (oncologists, OB/GYNs, cardiologists, neurologists, pediatricians) ordered tests through an online portal, paper requisitions, or integrated EHR workflows, with revenue generated through insurance billing (via Labcorp's in-network status with most major health plans after the acquisition) and a Financial Assistance Program offering $250-$299 ceiling pricing for uninsured patients. The company served 5+ million patients cumulatively. GTM was sales-led with enterprise field motions targeting provider accounts, supplemented by biopharma sponsored testing programs (Behind the Seizure, Navigate-APDS, Detect-MDYS, Discover-Dysplasias) and patient advocacy partnerships.

Invitae was founded in 2010 (per one source) or 2012 (per another and the bankruptcy filing), went public on NYSE under ticker NVTA in 2015, and pursued aggressive platform M&A including ArcherDX ($1.4B, 2020), Ciitizen ($325M, 2021), Genosity ($200M, 2021), and several others. The company never achieved profitability, filed Chapter 11 bankruptcy in February 2024 with liabilities of $1-10B against assets of $500M-$1B, and was acquired by Labcorp Genetics Inc. in May 2024 for approximately $239 million as a going-concern sale. Invitae now operates as a division of Labcorp, contributing an estimated $275-300M in annual revenue to its genetic specialty testing business.

Name

Invitae

Legal name

Invitae Corporation

Website

https://invitae.com

Company type

Private

Founded year

2012

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Invitae is a medical genetics company providing comprehensive NGS-based genetic testing across oncology, cardiology, neurology, women's health, and rare diseases to healthcare providers and over 5 million patients. Now operates as part of Labcorp's genetic testing division following a 2024 acquisition.

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Clinical genetic testing
• Hereditary cancer testing
• Next-generation sequencing
• Variant classification platform
• Molecular diagnostics

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genetic Testing Services: Invitae generates revenue through providing genetic testing services to healthcare providers and patients. Tests are billed to insurance (with Labcorp being in-network with most major health plans) or directly to patients. The company offers financial assistance programs for uninsured or underinsured patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Invitae provides clinical genetic testing services across hereditary cancer, cardiology, neurology, pediatric/rare disease, and proactive genetic risk assessment using next-generation sequencing and its proprietary Invitae Generation variant classification platform. Tests are ordered by healthcare providers via online portal or paper requisition, with specimens collected at Labcorp patient service centers or via physician offices, and results delivered with genetic counseling support at no additional cost. Following the 2024 acquisition by Labcorp, Invitae operates as part of Labcorp's genetic specialty testing business.

Product overview

Invitae is a genetic testing company that operates as a comprehensive genetic testing platform offering multiple product categories including hereditary cancer testing (breast, colorectal, ovarian, pancreatic, prostate), cardiology genetic testing, neurology genetic testing, pediatric and rare disease testing, and population health screening. The company provides a unified platform through its Invitae Generation technology for variant classification and the Gia chatbot for patient engagement. Testing services include multi-gene panels (Multi-Cancer Panel with 71 genes, Common Hereditary Cancers Panel with 49 genes), condition-specific panels (cardiology, neurology, pediatric), comprehensive genetic risk panels, and exome sequencing. The company also offers patient access programs including Invitae Unlock (for cardiomyopathy/arrhythmia) and sponsored testing programs (epilepsy, neuromuscular disorders, skeletal dysplasia). Invitae was acquired by Labcorp in 2024, with assets now integrated into Labcorp's genetic specialty testing business.

Differentiator

Problem solved

Functional benefit

Brands

• Invitae Unlock™: Testing access program where Invitae bills insurance, with no-charge testing for eligible uninsured patients
• Gia®
• Invitae Generation™

Products and services

• Hereditary Cancer Genetic Testing Comprehensive hereditary cancer testing panels covering multiple cancer types including breast, colorectal, ovarian, pancreatic, and prostate cancers to identify disease-causing gene variants for oncology providers and their patients.
• Invitae Multi-Cancer Panel Panel analyzing 71 genes associated with hereditary cancer conditions, providing comprehensive hereditary cancer risk assessment for oncology providers.
• Invitae Common Hereditary Cancers Panel Panel covering 49 genes commonly associated with hereditary cancer syndromes for oncology risk assessment.
• Invitae Hereditary Breast Cancer STAT Panel Fast turnaround panel analyzing up to 9 genes associated with hereditary breast cancer for time-sensitive oncology decisions.
• Invitae Hereditary Colorectal Cancer Panel Panel analyzing up to 33 genes associated with hereditary colorectal cancer and Lynch syndrome for oncology and gastroenterology providers.
• Cardio Genetic Testing Genetic testing for cardiovascular conditions including cardiomyopathies, arrhythmias, aortopathies, and lipidemias with average results delivered in 10-21 days, serving cardiology providers.
• Neurology Genetic Testing Neurological genetic testing panels covering epilepsy, neuromuscular conditions, neuropathies, and other brain, muscle, and nerve conditions to guide neurology treatment decisions and identify at-risk family members.
• Invitae Comprehensive Genetic Risk Panel Analyzes 163 genes associated with hereditary conditions for proactive health management in unaffected adult patients seeking genetic risk assessment.
• Invitae Cancer Genetic Risk Panel Analyzes 64 genes associated with hereditary cancer conditions for early detection and preventive measures in proactive health screening contexts.
• Gia (Genetic Information Assistant) Chatbot HIPAA-compliant clinical chatbot that facilitates virtual conversations with patients, collects family history, provides pre-test education, and facilitates automatic delivery of genetic test results. Used by over 100,000 patients with 92% satisfaction rate.
• Invitae Generation Platform Advanced machine learning and variant classification technology combining expert scientific teams with massive clinical database to provide precise genetic variant classification with 99%+ stability and reduced variants of uncertain significance.
• Labcorp Plasma Detect ID MRD Minimal residual disease testing using plasma-based detection for cancer monitoring, serving oncology providers tracking patient recurrence risk.
• Unlock Behind the Seizure Program Sponsored genetic testing program providing no-charge genetic testing and counseling for pediatric epilepsy patients who meet eligibility criteria.
• Invitae Unlock Programs Patient access programs that bill insurance when available and provide no-charge genetic testing for eligible patients without insurance coverage, including cardiomyopathy, arrhythmia, and other specialty testing programs.
• Invitae Exome Testing Whole exome sequencing service for comprehensive genetic analysis in pediatric and rare disease cases where targeted panels are non-diagnostic.
• Invitae Epilepsy Panel Sponsored panel analyzing up to 320 genes associated with both syndromic and nonsyndromic causes of epilepsy for neurology providers.
• Invitae Comprehensive Neuropathies Panel Panel analyzing up to 111 genes associated with hereditary neuropathies including Charcot-Marie-Tooth disease for neurology providers.
• Invitae Comprehensive Neuromuscular Disorders Panel Sponsored panel analyzing up to 230 genes associated with hereditary neuromuscular conditions including muscular dystrophies and inherited myopathies for neurology providers.

Quantifiable outcome

• 13.3% of cancer patients have pathogenic inherited variants detectable through genetic testing
• +5 more outcomes

Named customers3 records

Segments7 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Epic SystemscoreTechnology or Integration · 12 May 2026Labcorp (including Invitae) expanded its collaboration with Epic to integrate its full test menu into Epic's Aura platform. This builds on existing availability of Invitae genetic tests through the system, allowing clinicians to order tests and receive results directly within Epic workflows.
• LabcorpcoreTechnology or Integration · 5 August 2024Labcorp acquired Invitae's genetic testing services, digital health solutions, and health data services for approximately $239 million in August 2024. Invitae operates as part of Labcorp's genetics division, leveraging Labcorp's nationwide patient service centers and insurance network relationships.
• Biopharma Companies (Sponsored Testing Partners)minorStrategic or Co-development PartnerInvitae partners with biopharma companies on sponsored, no-charge testing programs for patients who meet eligibility criteria. Programs include conditions such as epilepsy (Behind the Seizure), primary immunodeficiency (Navigate-APDS), neuromuscular disease (Detect-MDYS), and skeletal dysplasia (Discover-Dysplasias).
• Patient Advocacy OrganizationsminorGTM or Marketing PartnerInvitae partners with patient advocacy organizations to support awareness, education, and access to genetic testing for specific conditions and patient communities.

Scale indicators8 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Natera: Natera is a direct competitor offering cell-free DNA and genetic testing across reproductive health, oncology, and organ transplantation. It competes head-to-head with Invitae in hereditary cancer and reproductive genetics with comparable NGS-based panels.
• Myriad Genetics: Myriad Genetics is a leading genetic testing company with strong positions in hereditary cancer (BRACAnalysis), prenatal testing, and psychiatric pharmacogenomics. It is one of Invitae's most established direct competitors in clinical genetics.
• Guardant Health: Guardant Health is a precision oncology company specializing in liquid biopsy and blood-based genomic profiling. It competes with Invitae's oncology testing offerings, including MRD and comprehensive genomic profiling.
• Foundation Medicine: Foundation Medicine, owned by Roche, provides comprehensive genomic profiling for solid tumors and hematologic malignancies. It directly competes with Invitae's oncology hereditary and somatic testing in the clinical and biopharma research markets.
• Exact Sciences: Exact Sciences is a molecular diagnostics company best known for Cologuard (colorectal cancer screening) and Oncotype DX. It competes with Invitae's hereditary cancer and oncology screening products in clinical settings.
• NeoGenomics: NeoGenomics specializes in oncology genetic and molecular testing, including solid tumor and liquid biopsy profiling, with strong biopharma services and clinical trial partnerships. It competes with Invitae in oncology-focused genetic testing.

Emerging players

• Color Health: Color Health offers genetic testing for hereditary cancer, cardiovascular conditions, and pharmacogenomics, with a focus on population health and employer-sponsored programs. It competes with Invitae in the proactive genetic risk assessment segment.
• Tempus AI: Tempus AI combines genomic sequencing with AI-driven clinical decision support across oncology and other specialties. It overlaps with Invitae's oncology testing portfolio and increasingly with the data/AI infrastructure that Ciitizen was acquired to build.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory networks in the U.S. and offers extensive genetic and molecular diagnostic testing. As a broad incumbent, it overlaps with Invitae across multiple testing categories and serves many of the same provider customers.
• Revvity (formerly PerkinElmer): Revvity offers applied genomics, reproductive health, and newborn screening diagnostics through its life sciences business. It competes with Invitae in reproductive and pediatric genetic testing markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InVitae
• Facebookfacebook.com/136602503165993
• LinkedInlinkedin.com/company/invitae
• Instagraminstagram.com/invitae

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds13 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A14 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invitae